Fritextsökning
Innehållstyper
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...
-
600 million SEK for life science - "Should not be the country of moderation"
Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.
-
ZEISS presents the "Quality Innovation Summit"
A global event on the future of quality assurance.
-
Computed tomography in measurement of medical plastic products
Watch the recordings from ZEISS Quality Innovation Summit.
-
Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide
AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
Explore the latest trends and innovations in quality assurance and manufacturing
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
Quotient Sciences Limited
-
CTC Clinical Trial Consultants AB
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
Sofia Wallström is Lif's new CEO
Sofia Wallström has been appointed as the new CEO of the industry organization Lif, the trade association for the research-based pharmaceutical industry in Sweden.
-
Spatial Biology Studies in Lung Tissue using Spectral Microscopy
Spectral imaging with the ZEISS LSM 980 laser scanning confocal enables more complex studies of cell-cell interactions and locations in immunology research.
-
ZEISS O-INSPECT duo: The multifunctional measuring machine
ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.
-
Affibody AB
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...